Blincyto (blinatumomab), a bispecific antibody first approved for cancer in 2014, has received a new indication from the US Food and Drug Administration, extending its coverage for the treatment of B cell acute lymphoblastic leukaemia (B-ALL). B-ALL, an aggressive leukaemia, is the most common type of acute lymphoblastic leukaemia.
The new indication is for the treatment of adults and children from the age of one month for CD19 positive Philadelphia chromosome-negative B cell precursor acute lymphoblastic leukaemia.
